Hugh M. Cole, MBA has held a number of senior executive positions at biopharma companies, including most recently Chief Operating Officer at Jounce Therapeutics. Hugh also served on the Board of Directors of Astria Therapeutics from 2019 until its acquisition by BioCryst in 2026. Prior to Jounce, Hugh was the Chief Business Officer at ARIAD Pharmaceuticals, a publicly held pharmaceutical company acquired by Takeda in 2017. Prior to ARIAD, he held positions of increasing responsibility at Shire Pharmaceuticals, including Senior Vice President, Strategic Planning and Program Management, HAE Global Franchise Leader, and Head of Business Development for Shire’s rare disease business. Hugh holds an A.B. in Chemistry from Harvard University and an MBA in Health Care Management and Finance from the Wharton School at the University of Pennsylvania.
Team
